Harnessing the immune system for ovarian cancer therapy Journal Article
| Authors: | Odunsi, K.; Sabbatini, P. |
| Article Title: | Harnessing the immune system for ovarian cancer therapy |
| Abstract: | The clinical course of ovarian cancer is often marked by periods of relapse and remission until chemo-resistance develops. Patients in remission with minimal disease burdens are ideally suited for the evaluation of immune-based strategies. Major obstacles to the development of successful immune strategies include the identification of tumor-restricted immunogenic targets, generation of a sufficient immune response to cause tumor rejection, and approaches to overcome evasion of immune attack. Many questions remain as optimal strategies are developed, which include: (i) What is the best antigen form (e.g. peptides, proteins or tumor lysates)? (ii) What are the appropriate adjuvants? (iii) Are mono-valent or multi-valent vaccines likely to be more effective? (iv) What is the optimal frequency and duration of vaccination? (v) How should antigen-specific responses be monitored? and (vi) How should the anti-cancer response be maintained? In this review, we explore representative examples of immune strategies under investigation for patients with ovarian carcinoma which illustrate many of these issues. Basic principles generic to all these immunotherapeutic approaches will also be discussed. © 2008 The Authors Journal compilation © 2008 Blackwell Munksgaard. |
| Keywords: | cancer survival; protein expression; unclassified drug; overall survival; clinical trial; review; placebo; drug efficacy; nonhuman; unspecified side effect; ovarian neoplasms; dendritic cell vaccine; cancer immunotherapy; immune system; protein targeting; tumor antigen; ovary; cellular immunity; antigens, neoplasm; cancer vaccine; cancer vaccines; ny eso 1 antigen; major histocompatibility antigen class 2; cancer immunization; ovary carcinoma; tumor immunity; dna vaccine; orchitis; ca 125 antigen; lymphocytic infiltration; tumor cell vaccine; humoral immunity; absence of side effects; adoptive immunotherapy; immunotherapy, adoptive; major histocompatibility antigen class 1; ny-eso-1; immunoediting; abagovomab; anti-idiotype; tumor infiltrating lymphocytes; tumorantigens; aca 125; idiotypic antibody vaccine; keyhole limpet hemocyanin antigen; ny eso 1 antigen vaccine; oregovomab |
| Journal Title: | American Journal of Reproductive Immunology |
| Volume: | 59 |
| Issue: | 1 |
| ISSN: | 1046-7408 |
| Publisher: | Blackwell Publishing |
| Date Published: | 2008-01-01 |
| Start Page: | 62 |
| End Page: | 74 |
| Language: | English |
| DOI: | 10.1111/j.1600-0897.2007.00560.x |
| PUBMED: | 18154597 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 8" - "Export Date: 17 November 2011" - "CODEN: AAJID" - "Source: Scopus" |
